2023 ASCO Annual Meeting Coverage

Trastuzumab deruxtecan could offer a tumor-agnostic treatment option for patients with HER2-expressing malignancies.

Autologous anti-CD19 CAR T-cell therapy significantly improves overall survival versus standard care for patients with relapsed or refractory large B-cell lymphoma.

The KEYNOTE-671 trial points to a significant improvement in event-free survival for patients with early-stage, non-small-cell lung cancer with use of pembrolizumab before and after surgery.

The INDIGO study has shown a significant progression-free survival benefit of vorasidenib in people with grade 2 glioma with IDH mutations.

Preoperative pelvic radiotherapy can be omitted in patients with locally advanced rectal cancer who respond to neoadjuvant chemotherapy, say the PROSPECT investigators.

Supplementing endocrine therapy with ribociclib significantly decreases the relapse risk in people with hormone receptor-positive, HER2-negative, early breast cancer.